Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


European Positive Opinions For Botox In Urinary Incontinence To Boost Allergan's Urology Focus

This article was originally published in The Pink Sheet Daily

Executive Summary

Allergen gains positive opinions in Europe for use of Botox in urinary incontinence associated with multiple sclerosis or spinal cord injury, paving the way for the company's further expansion into urology.

You may also be interested in...

Ipsen's New Chief Outlines Growth Plans In U.S., Emerging Markets

Tighter product focus and streamlined R&D will help double sales and triple profits by 2020, says CEO Marc de Garidel.

Botox For Migraine: How Will The Market Size Up?

The U.S. approval of Allergan Inc.’s Botox (onabotulinumtoxinA) to treat chronic migraines will surely be a boon to the company, but anyone attempting to pin down the market impact of the approval will encounter enough variables to cause a splitting headache.

Allergan Buys Global Rights To Serenity's Phase III Drug For Frequent Nighttime Urination

Allergan also will have right of first refusal for Ser-120 in pediatric bedwetting, though this use is in early stage development.

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts